InvestSMART

Alterity Therapeutics Limited (ASX: ATH) - Announcements

- Current share price for ATH : $0.255

ASX company news and announcements for Alterity Therapeutics Limited (ATH) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Alterity Therapeutics Limited (ATH) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Alterity Therapeutics Limited (ATH), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Alterity Therapeutics Limited (ATH)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$58 Form 603 Notice lodged by Bank of New York Mellon 8 May 2019 9:31AM $0.044 $0.255 risen by 479.55%
$58 Becoming a substantial holder 8 May 2019 8:25AM $0.044 $0.255 risen by 479.55%
$58 Alterity presents initial Phase 1 clinical trial data at AAN 6 May 2019 9:47AM $0.040 $0.255 risen by 537.50%
$58 ATH presents at the American Academy of Neurology 3 May 2019 2:27PM $0.040 $0.255 risen by 537.50%
$58 Appendix 4C - quarterly 17 Apr 2019 9:02AM $0.050 $0.255 risen by 410%

576 - 580 of 580 results

Page 24 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.